2019 ARIA: care pathways for allergic rhinitis in Russia

Cover Page
  • Authors: Khaitov M.R.1, Namazova-Baranova LS.2,3, Ilyina NI.1, Kurbacheva OM.1, Bachert C.4, Hellings P.W5, Pfaar O.6, Schunemann H.J7, Wallace D8, Bedbrook A9, Czarlewski W10, Bousquet J.9
  • Affiliations:
    1. National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
    2. Central Clinical Hospital of the Russian Academy of Sciences is a multidiscipline medical centre
    3. Pirogov Medical University
    4. University of Stockholm
    5. University Hospitals Leuven
    6. University Hospital Marburg
    7. McMaster University
    8. Nova Southeastern University
    9. MACVIA-France, Fondation partenariale FMC VIA-LR
    10. Medical Consulting Czarlewski
  • Issue: Vol 17, No 1 (2020)
  • Pages: 7-22
  • Section: Articles
  • URL: https://rusalljournal.ru/raj/article/view/1344
  • DOI: https://doi.org/10.36691/RAJ.2020.17.1.001
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


One of the most common chronic upper respiratory diseases worldwide is allergic rhinitis (AR). Despite advances in understanding the mechanisms of allergic inflammation, the symptoms of AR in most cases are not completely controlled by modern treatment methods. Allergic rhinitis is a precursor and predisposing factor for the development of other respiratory diseases, one of which is asthma. Diagnosis of AR is being actively conducted, but there is still a serious problem of uncontrolled and chaotic treatment of patients, so it is necessary to provide comprehensive medical care within the national health system. ARIA aims to develop and apply internationally recommendations for the management of patients with allergic respiratory diseases. In collaboration with other international associations that deal with the treatment and diagnosis of allergies and respiratory diseases, regulations and programs have been developed for the treatment of patients with AR, as well as when it is combined with asthma, which form the basis of ARIA. This document has been adapted for use in the field of healthcare in the Russian Federation and covers key issues related to the management of patients with AR and in combination with AR and asthma.

Restricted Access

Musa Rakhimovich Khaitov

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Email: mr.khaitov@nrcii.ru

L Seymurovna Namazova-Baranova

Central Clinical Hospital of the Russian Academy of Sciences is a multidiscipline medical centre; Pirogov Medical University

Email: Isnamazova@yandex.ru

N Ivanovna Ilyina

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru

O Mikhaylovna Kurbacheva

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Email: kurbacheva@gmail.com

Claus Bachert

University of Stockholm

Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent University Hospital, Ghent, Belgium Division of ENT Diseases, CLINTEC, Karolinska Institute

Peter W Hellings

University Hospitals Leuven

Department of Otorhinolaryngology

Oliver Pfaar

University Hospital Marburg

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy

Holger J Schunemann

McMaster University

Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy

D Wallace

Nova Southeastern University

A Bedbrook

MACVIA-France, Fondation partenariale FMC VIA-LR

W Czarlewski

Medical Consulting Czarlewski

Jean Bousquet

MACVIA-France, Fondation partenariale FMC VIA-LR

PhD, Professor

  1. Bousquet J, Amavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45. doi: 10.1186/s13601-018-0227-6.
  2. Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pepin JL et al. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy 2018;8:36. doi: 10.1186/s13601-018-0221-z.
  3. Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BmJ. 1998;316(7125):133-137. doi: 10.1136/bmj.316.7125.133.
  4. Hujala A, Taskinen H, Rissanen S. In: Richardson E, van Ginneken E, editors. How to support integration to promote care for people with multimorbidity in Europe? European Observatory Policy Briefs. Copenhagen (Denmark). Available at: http://www.euro.who.int/_data/assets/pdf_ file/0008/337589/PB_26.pdf. The link is active on 02.03.2020.
  5. Palmer K, Marengoni A, Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F et al. Multimorbidity care model: Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy. 2018;122(1):4-11. doi: 10.1016/j.healthpol.2017.09.006.
  6. Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A et al. Integrated care pathways for airway diseases (AIR-WAYS-ICPs). Eur Respir J. 2014;44(2):304-323. doi: 10.1183/09031936.00014614.
  7. Bousquet J, Onorato GL, Bachert C, Barbolini M, Bedbrook A, Bjermer L et al. CHRODIS criteria applied to the MASK (MACVA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clin Transl Allergy. 2017;7:37. doi: 10.1186/s13601-017-0173-8.
  8. Hellings PW, Borrelli D, Pietikainen S, Agache I, Akdis C, Bachert C et al. European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). Clin Transl Allergy. 2017;7:49. doi: 10.1186/s13601-017-0186-9.
  9. Федоскова ТГ, Ильина НИ. Аллергические заболевания в клинической практике. РМЖ. 2005;15:1022 [Fedoskova TG, Ilina NI. Allergic deseasesd in Clinical Practice. RMJ. 2005;15:1022 (In Russ.)].
  10. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2019. Доступно по: http://www.pulmonology.ru. Ссылка активна на 05.02.2020 [Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu bronkhial’noi astmy. 2019) Available at: http://www. pulmonology.ru. The link is active on 05.02.2020. (In Russ.)].
  11. Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682-688. doi: 10.1016/j.jaip.2016.02.006.
  12. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T Hunter NL et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016; 375(23):2293-2297. doi: 10.1056/NEJMsb1609216.
  13. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476. DOI: 10.1016/j. jaci.2010.06.047.
  14. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950-958. DOI: 10.1016/j. jaci.2017.03.050.
  15. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T Finegold I et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511. DOI: 10.1016/j. anai.2017.08.012.
  16. Bousquet J, Devillier P, Anto JM, Bewick M, Haahtela T Arnavielhe S et al. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018;73(8):1622-1631. doi: 10.1111/all.13448.
  17. Bousquet J, Devillier P, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy. 2018;73(9):1763-1774. doi: 10.1111/all.13406.
  18. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-374. DOI: 10.1016/j. jaci.2016.03.025.
  19. Courbis AL, Murray RB, Arnavielhe S, Caimmi D, Bedbrook A, Van Eerd M et al. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018;48(12):1640-1653. doi: 10.1111/cea.13230.
  20. Horak F, Bruttmann G, Pedrali P, Weeke B, Frolund L, Wolff HH et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimit-telforschung. 1988;38(1):124-128.
  21. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168-173. doi: 10.1016/j.anai.2010.06.008.
  22. Kaszuba SM, Baroody FM, de Tineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticoste roid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581-2587. doi: 10.1001/archinte.161.21.2581.
  23. Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D et al. Treatments for Seasonal Allergic Rhinitis. AHRQ Comparative Effectiveness Reviews. Rockville (MD). Available at: https://effectivehealthcare.ahrq.gov/products/allergy-sea-sonal/research-protocol. The link is active on 05.01.2020.
  24. “Draft Guidance for Industry: Allergic Rhinitis: Clinical Development Programs for Drug Products”, Food and Drug Administration, CDER. Available at: http://wwwfdagov/cder/ guidance/indexhtm. The link is active on 05.01.2020.
  25. Allergic Rhinitis: developping drug products for treatment. Guidance for industry.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2016 Clinical/ Medical Revision 1. Available at: https://wwwfdagov/down-loads/drugs/guidances/ucm071293pdf. The link is active on 05.01.2020.
  26. Katial RK, Salapatek AM, Patel P. Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc. 2009;30(6):595-604. doi: 10.2500/aap.2009.30.3291.
  27. Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21(4):499-503. doi: 10.2500/ajr.2007.21.3058.
  28. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732. doi: 10.1016/j.jaip.2018.01.031.
  29. Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137(6):918-924.
  30. Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmerer RO Jr. et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc. 2011;32(3):221-229. doi: 10.2500/aap.2011.32.3444.
  31. Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22(1):151-157. doi: 10.1185/030079906X80305.
  32. Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24(6):1833-1840. doi: 10.1185/03007990802155792.
  33. Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R et al. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015;45(8):1346-1355.
  34. Sleurs K, Seys S, Bousquet J, Fokkens W, Gorris S, Pugin B et al. Mobile health tools for the management of chronic respiratory diseases. Allergy. 2019(7):1292-1306. DOI: 10.1111/ all.13720.
  35. Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47. doi: 10.1186/s13601-019-0289-0.
  36. Menditto E, Guerriero F, Orlando V, Crola C, Di Somma C, Illario M et al. Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population. J Aging Res. 2015;2015:682503. doi: 10.1155/2015/682503.
  37. Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med. 2017;23(1):21-26. DOI: 10.1097/ MCP.0000000000000336.
  38. Pizzulli A, Perna S, Florack J, Pizzulli A, Giordani P, Tripodi S et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2014;44(10):1246-1254. doi: 10.1111/cea.12386.
  39. Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. doi: 10.1186/s13601-015-0083-6.
  40. Bousquet J, Murray R, Price D, Somekh D, Munter L, Phillips J et al. The allergic allergist behaves like a patient. Ann Allergy Asthma Immunol. 2018;121(6):741-742. DOI: 10.1016/j. anai.2018.07.034.
  41. Patel P, Patel D, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J. 2008;87(6):340-353.
  42. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):1-84. doi: 10.1016/j.jaci.2008.06.003.
  43. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102-1116. doi: 10.1111/all.12235.
  44. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017;47(7):856-889. doi: 10.1111/cea.12953.
  45. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289. doi: 10.1016/j.jaci.2012.01.077.
  46. Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc. 2013;34(4):301-311. doi: 10.2500/aap.2013.34.3676.
  47. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197-206. doi: 10.1177/0194599814562166.
  48. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015; 152(1):1-43. doi: 10.1177/0194599814561600.
  49. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. DOI: 10.1186/ s13601-018-0210-2.
  50. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466. doi: 10.1111/j.1398-9995.2009.02325.x.
  51. Halken S, Larenas-Linnemann D, Roberts G, Calderon MA, Angier E, Pfaar O et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728-745. doi: 10.1111/pai.12807.
  52. Bonertz A, Roberts G, Slater JE, Bridgewater J, Rabin RL, Hoefnagel M et al. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy 2018;73(4):816-826. doi: 10.1111/all.13357.
  53. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018;73(4):765-798. doi: 10.1111/all.13317.
  54. Ryan D, Gerth van Wijk R, Angier E, Kristiansen M, Zaman H, Sheikh A et al. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018;73(4):827-836. doi: 10.1111/all.13264.
  55. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-medi-ated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282-319. doi: 10.1007/s40629-014-0032-2.
  56. Muraro A, Roberts G, Halken S, Agache I, Angier E, Fernandez-Rivas M et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018;73(4):739-743. doi: 10.1111/all.13420.
  57. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018;73(1):165-177. doi: 10.1111/all.13213.
  58. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437-452. doi: 10.1002/hec.864.
  59. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):41-322. doi: 10.3310/hta17270.
  60. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 (86):8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
  61. Larenas-Linnemann DES, Antolin-Amerigo D, Parisi C, Nakonechna A, Luna-Pech JA, Wedi B et al. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. Allergy. 2018;73(3):664-672. doi: 10.1111/all.13316.
  62. Bonertz A, Roberts GC, Hoefnagel M, Timon M, Slater JE, Rabin RL et al. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018;73(1):64-76. doi: 10.1111/all.13266.
  63. Committee for medicinal products for human use (CPMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London. 2008. Available at: https://www.ema.europa.eu/en/documents/ scientific-guideline/guideline-allergen-products-produc-tion-quality-issues_en.pdf. The link is active on 05.01.2020.
  64. Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J. 2016;9(1):33. doi: 10.1186/s40413-016-0122-3.
  65. Bachert C, Larche M, Bonini S, Canonica GW Kundig T Larenas-Linnemann D et al. Allergen immunotherapy on the way to product-based evaluation-a WAO statement. World Allergy Organ J. 2015;8(1):29. doi: 10.1186/s40413-015-0078-8. '
  66. Wheatley L, Wood R, Nadeau K, Liu A, Zoratti E, Bacharier L et al. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy. An NIAID/ AHRQ workshop. J Allergy Clin Immunol. 2019;143(5):1711-1726. doi: 10.1016/j.jaci.2019.01.032.
  67. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81(5):401-405. doi: 10.1016/S1081-1206(10)63136-5.
  68. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345. doi: 10.1016/j.jaci.2007.07.046.
  69. Nelson H, Blaiss M, Nolte H, Wurtz SO, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy. 2013;68(2):252-255. doi: 10.1111/all.12074.
  70. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725. doi: 10.1016/j.jaci.2011.12.973.
  71. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569-574. doi: 10.1016/j.jaci.2009.10.060.
  72. Passalacqua G, Baena-Cagnani CE, Bousquet J, Canonica GW, Casale TB, Cox L et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132(1):93-98. doi: 10.1016/j.jaci.2013.03.039.
  73. Baiardini I, Puggioni F, Menoni S, Boot JD, Diamant Z, Braido F et al. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir Med. 2013;107(3):361-367. DOI: 10.1016/j. rmed.2012.11.004.
  74. Nam YH, Lee SK. Physician’s recommendation and explanation is important in the initiation and maintenance of allergen immunotherapy. Patient Prefer Adherence. 2017;11:381-387. doi: 10.2147/PPA.S118368.
  75. Chivato T Alvarez-Calderon P, Panizo C, Abengozar R, Alias C, Al-Baech A et al. Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhi-noconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain. Clin Mol Allergy. 2017;15:1. doi: 10.1186/s12948-016-0057-9.
  76. Skoner DP, Blaiss MS, Dykewicz MS, Smith N, Leatherman B, Bielory L et al. The Allergies, Immunotherapy, and Rhi-noconjunctivitiS (AIRS) survey: patients’ experience with allergen immunotherapy. Allergy Asthma Proc. 2014;35(3):219-226. doi: 10.2500/aap.2014.35.3752.
  77. Pitsios C, Dietis N. Ways to increase adherence to allergen immunotherapy. Curr Med Res Opin. 2019;35(6):1027-1031. doi: 10.1080/03007995.2018.1552044.
  78. Bender BG, Lockey RF. Solving the Problem of Nonadherence to Immunotherapy. Immunol Allergy Clin North Am. 2016;36(1):205-213. doi: 10.1016/j.iac.2015.08.014.
  79. Bachert C, Grafin-von-Strachwitz-Helmstatt K. Zur Diskussion gestellt: Der Arzt und die Spezifische Immuntherapie im Spannungsfeld von Leitlinie, Wirtschaftlichkeit und Medizin-recht. Allergologie. 2016;39:381-388.
  80. Kuehl BL, Abdulnour S, O’Dell M, Kyle TK. Understanding the role of the healthcare professional in patient self-management of allergic rhinitis. SAGE Open Med. 2015;3:2050312115595822. doi: 10.1177/2050312115595822.
  81. Bosnic-Anticevich S, Kritikos V, Carter V, Yan KY Armour C, Ryan D et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia. J Asthma. 2018;55(6):684-94. doi: 10.1080/02770903.2017.1353611.
  82. Bosnic-Anticevich S, Costa E, Menditto E, Lourenco O, Novellino E, Bialek S et al. ARIA pharmacy 2018 «Allergic rhinitis care pathways for community pharmacy». Allergy 2019;74(7):1219-1236. doi: 10.1111/all.13701.
  83. Jutel M, Papadopoulos NG, Gronlund H, Hoffman HJ, Bohle B, Hellings P et al. Recommendations for the allergy management in the primary care. Allergy. 2014;69(6):708-718. doi: 10.1111/all.12382.
  84. Finlay I, Egner W. Allergy: will we ever meet the unmet need? J R Soc Med. 2010;103(11):430-431. DOI: 10.1258/ jrsm.2010.100253.
  85. Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T Agache I et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297-1305.
  86. Pinnock H, Thomas M, Tsiligianni I, Lisspers K, Ostrem A, Stallberg B et al. The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J. 2010;19(1):1-20. doi: 10.4104/pcrj.2010.00021.
  87. Shehata Y, Ross M, Sheikh A. Undergraduate allergy teaching in a UK medical school: comparison of the described and delivered curriculum. Prim Care Respir J. 2007;16(1):16-21. doi: 10.3132/pcrj.2007.00004.
  88. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(82):1-20. doi: 10.1111/j.1398-9995.2006.01219_1.x.
  89. Landi M, Meglio P, Praitano E, Lombardi C, Passalacqua G, Canonica GW. The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clin Mol Allergy. 2015;13(1):15. doi: 10.1186/s12948-015-0021-0.
  90. Canonica GW, Bachert C, Hellings P, Ryan D, Valovirta E, Wickman M et al. Allergen Immunotherapy (AIT): a prototype of Precision Medicine. World Allergy Organ J. 2015;8(1):31. doi: 10.1186/s40413-015-0079-7.
  91. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE et al. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6(1):17. doi: 10.1186/1939-4551-6-17.
  92. Lee J, Kronborg C, O’Hehir RE, Hew M. Who’s at risk of thunderstorm asthma? The ryegrass pollen trifecta and lessons learnt from the Melbourne thunderstorm epidemic. Respir Med. 2017;132:146-148. doi: 10.1016/j.rmed.2017.10.012.
  93. O’Hehir rE, Varese NP, Deckert K, Zubrinich CM, van Zelm MC, Rolland JM et al. Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. Am J Respir Crit Care Med. 2018;198(1):126-128. doi: 10.1164/rccm.201711-2337LE.
  94. Pitsios C, Demoly P, Bilo MB, Gerth van Wijk R, Pfaar O, Sturm GJ et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70(8): 897-909.
  95. Global Strategy for Asthma Management and Prevention (2018 update). wms-GINA-2018-report-V13-002pdf. 2018. doi: 10.1111/all.12638.
  96. Summary of product characteristics. Acarizax 12 SQ-HDM oral lyophilisate. European Medicines Agency. Available at: https://mricts-mrpeu/Human/Downloads/ DE_H_1947_001_FinalSPCpdf. The link is active on 05.01.2020.
  97. Amaral R, Fonseca JA, Jacinto T, Pereira AM, Malinovschi A, Janson C et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007-2012. Clin Transl Allergy. 2018;8:13. doi: 10.1186/s13601-018-0201-3.
  98. Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;73(12):2352-2363. doi: 10.1111/all.13544.
  99. Penagos M, Eifan AO, Durham SR, Scadding GW Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. Curr Treat Options Allergy. 2018;5(3):275-290. doi: 10.1007/s40521-018-0176-2.
  100. Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538. DOI: 10.1016/j. jaci.2017.06.014.
  101. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251-256. doi: 10.1067/mai.2002.121317.
  102. Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18-29. doi: 10.1111/pai.12661.
  103. Bozek A, Kolodziejczyk K, Kozlowska R, Canonica GW. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial. Clin Transl Allergy. 2017;7:43. doi: 10.1186/s13601-017-0180-9.
  104. Bousquet J, Arnavielhe S, Bedbrook A, Fonseca J, Morais Almeida M, Todo Bom A et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy. 2018;73(2):505-510. doi: 10.1111/all.13307.
  105. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854-867. doi: 10.1111/all.12383.

Views

Abstract - 223

PDF (Russian) - 7

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies